Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 31, 2024

SELL
$0.9 - $1.06 $1,562 - $1,840
-1,736 Reduced 21.47%
6,350 $6,000
Q2 2023

Aug 14, 2023

SELL
$1.1 - $1.54 $735 - $1,030
-669 Reduced 7.64%
8,086 $9,000
Q1 2023

May 08, 2023

BUY
$1.19 - $2.09 $10,174 - $17,869
8,550 Added 4170.73%
8,755 $11,000
Q4 2022

Feb 13, 2023

BUY
$1.67 - $2.35 $342 - $481
205 New
205 $0
Q4 2021

Feb 14, 2022

SELL
$5.23 - $7.18 $21,986 - $30,184
-4,204 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$5.94 - $8.75 $184 - $271
-31 Reduced 0.73%
4,204 $26,000
Q2 2021

Aug 16, 2021

SELL
$7.54 - $9.79 $1,606 - $2,085
-213 Reduced 4.79%
4,235 $34,000
Q1 2021

May 13, 2021

BUY
$4.76 - $11.25 $21,172 - $50,040
4,448 New
4,448 $43,000
Q4 2019

Feb 14, 2020

SELL
$1.3 - $2.72 $153 - $320
-118 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$1.93 - $4.21 $1,874 - $4,087
-971 Reduced 89.16%
118 $1,000
Q2 2018

Aug 10, 2018

BUY
$4.43 - $5.14 $748 - $868
169 Added 18.37%
1,089 $5,000
Q1 2018

May 09, 2018

BUY
$4.65 - $5.9 $3,031 - $3,846
652 Added 243.28%
920 $5,000
Q4 2017

Feb 14, 2018

BUY
$4.32 - $5.52 $1,157 - $1,479
268
268 $0

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $77.1M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.